bioAffinity Technologies, Inc. (BIAF): Capital Expenditures

Annual figures by period end, from SEC filings.

$60.6K

Year ended 2025-12-31

$92.0K

Trailing 12 months to 2026-06-30

-34.9%

3-year compound annual growth

2022-12-31 Capital Expenditures (USD) 2025-12-31

Period ended	Capital Expenditures	Change YoY	Source filing
2025-12-31	$60.6K	-23.4%	2026-03-16, From 2025-01-01
2024-12-31	$79.1K	+245.3%	2026-03-16, From 2024-01-01
2023-12-31	$22.9K	-89.6%	2025-03-31, From 2023-01-01
2022-12-31	$220.0K	n/a	2024-04-01, From 2022-01-01

Capital Expenditures at similar companies

Companies with the same SEC industry code (Services-Commercial Physical & Biological Research), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Capital Expenditures	Change YoY
bioAffinity Technologies, Inc. (BIAF)	2025-12-31	$60.6K	-23.4%
Absci Corp (ABSI)	2025-12-31	$1.11M	+174.0%
Foxo Technologies Inc. (FOXO)	2025-12-31	$62.0K	n/a
OmniAb, Inc. (OABI)	2025-12-31	$565.0K	-69.9%
iSpecimen Inc. (ISPC)	2025-12-31	$454	-98.6%
OneMedNet Corp (ONMD)	2025-12-31	$13.0K	-74.5%
MaxCyte, Inc. (MXCT)	2025-12-31	$1.77M	+7.1%
NRC Health (NRC)	2025-12-31	$10.71M	-30.7%
Medpace Holdings, Inc. (MEDP)	2025-12-31	$31.36M	-14.2%

Compare BIAF, ABSI, FOXO, OABI side by side · Screen every company in Services-Commercial Physical & Biological Research ↗